-+ 0.00%
-+ 0.00%
-+ 0.00%

RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation

PUBT·08/25/2026 00:34:37
Listen to the news
RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation
  • RemeGen posted 2026 H1 domestic drug sales of RMB 1.4 billion, citing continued growth and improving margins.
  • Cash and cash equivalents totaled RMB 3.84 billion as of 6/30/2026, supporting operations and development spending.
  • Commercial portfolio includes telitacicept and disitamab vedotin, both launched in China, with multiple late-stage label-expansion programs highlighted.
  • Partnership package covers four drugs with potential value above USD 12 billion, including out-licensing deals with Vor Bio, Pfizer, AbbVie, Santen.
  • Telitacicept Phase 3 readouts cited for gMG, Sjögren’s disease, IgA nephropathy; IgAN study showed 55% placebo-adjusted 24-hour UPCR reduction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.